New Delhi: The Subject Expert Committee (SEC) at the Central Drugs Standard Control Organisation (CDSCO) has recommended that the country's top drug regulator grant permission for phase 3 clinical trial using Thymosin @-1 injection 1.6 mg on moderate to severe COVID-19 patients, said a senior health ministry official on Wednesday.The senior government official said: "Domestic pharma giant Gufic Bioscience has submitted its application to DCGI for its permission to use Thymosin @-1 injection 1.6 mg on coronavirus patients.
Our subject experts committee reviewed it thoroughly and further recommended to the Drugs Controller General of India (DGCI) for its consideration."So far, Thymosin @-1 injection 1.6 mg has been used in the treatment of.